Melanotan II (MT-II) is a synthetic, cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH), originally developed at the University of Arizona in the 1980s as a sunless-tanning research compound. It targets both the MC1R receptor (pigmentation) and the MC4R receptor (sexual function, appetite), and it was never approved by the FDA for any indication. WADA lists it as a prohibited substance, and the FDA has issued multiple warning letters against it.

Safety note. This article is educational and for personal recordkeeping only. It gives no dose, unit count, concentration, reconstitution, injection technique, vendor, cycle, or stacking instructions. Peptide decisions, especially gray-market or research-use products, belong with a licensed professional.

What is Melanotan II?

MT-II is structurally related to—but distinct from—two peptides that did reach approval: afamelanotide (Scenesse, EU-approved for erythropoietic protoporphyria, an MC1R-selective drug) and bremelanotide (Vyleesi, FDA-approved for HSDD, an MC4R-targeted drug). Neither approval covers MT-II. The University of Arizona research program eventually pivoted to those more selective analogs; the MT-II molecule itself was not advanced to approval partly because its dual MC1R/MC4R activity complicated single-indication drug development.

Community use focuses on tanning and libido, but the MC4R pathway driving those effects also affects blood pressure, appetite, and nausea—which is why flushing and nausea are among the most commonly reported side effects. Known concerns include changes to existing moles or nevi via MC1R stimulation. There is no legitimate prescriber pathway for MT-II in the US, and the FDA considers it an unapproved drug. For a broader safety frame, read Research Peptide Safety Questions Before You Start.

What do people use Melanotan II for?

People most often mention Melanotan II for sunless tanning, appetite changes, libido, and comparisons with PT-141 or afamelanotide. Those are community claims, not proof. The same claim can mean very different things depending on whether it comes from a clinical label, a small trial, an animal model, a vendor page, or a forum anecdote.

Use the claim as a filing label, not a conclusion. Write down the purpose in plain language: what outcome is being watched, what else changed at the same time, and what would count as a reason to stop and ask for care.

How do people discuss using Melanotan II?

Reported use usually means injection-style products, nasal sprays, tanning forums, and influencer posts that can make unapproved products look routine. The useful part to record is context, not numbers: why it was considered, who reviewed it, what else was already in the stack, and what stop signs were discussed.

Do not copy online calculators, vendor protocols, or preparation walkthroughs into a personal plan. A peptide protocol log should preserve professional guidance and observations, not turn a social post into instructions.

What does the research say?

FDA safety material lists serious adverse-event case reports for Melanotan II, including melanoma-related concerns and other severe reactions.

A good research note separates mechanism, animal data, human trial data, approval status, and real-world anecdotes. When those buckets get mixed together, a peptide can look more proven than it is.

What should a beginner track?

Track skin changes, mole photos only for discussion with a dermatologist, sun exposure, symptoms, and any product label or source concern without saving vendor instructions as a plan.

In Dosefi, keep the entry boring and complete: date, category, source type, professional guidance, symptoms, photos only when useful, and the question you want answered next. A clear log is not proof that the peptide works. It is a way to avoid rewriting the story after the fact.

What red flags matter most?

The major red flag is using it as a sunscreen substitute or ignoring mole changes. Skin cancer risk, pigmentation changes, and cardiovascular symptoms need professional care.

Also pause when a product is sold only through anonymous vendors, when a blend hides individual ingredients, when the seller offers medical claims without medical oversight, or when the only evidence is a before-and-after post. Serious symptoms should be handled as health events, not as content to troubleshoot in comments.

Sources